Autonomous Blood Drawing Optimization and Performance Testing

Last updated: May 17, 2024
Sponsor: Vitestro B.V.
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Venipuncture Device (VD)

Clinical Study ID

NCT05878483
NL80965.000.22
  • Ages > 16
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this pre-market clinical study is to evaluate the performance (efficacy) and safety of an autonomous blood drawing device (Venipuncture Device).

The study consists of several phases (A, B1, B2, C1, C2, 0).

Phase B1 is a confirmatory, Pivotal Clinical Study, required for regulatory approval, in which non-inferiority should be demonstrated in comparison to manual blood drawing.

Phases A, B2, C1, C2 are all exploratory studies, in which the technology and usability is further improved and tested. Phase 0 is an exploratory study for non-invasive technology testing (for example for improvement of ultrasound detection).

The study locations are outpatient blood drawing departments, in which patients are included as subjects. Additionally, in Phase A and C1, a small number of volunteers is included in a non-hospital site (Vitestro Site).

Eligibility Criteria

Inclusion

Inclusion Criteria:

• Age ≥16 years.

Exclusion

Exclusion Criteria:

  • Unable to follow instructions, due to mental disability and/or incapacity

  • Unable to use device correctly due to physical impairment or disability (for examplea patient with severe contractures or deformities)

  • No venipuncture possible in cubital fossa of both arms (for example: afteramputation of both arms)

  • No venipuncture possible in cubital fossa due to contra-indications in both arms (for example: tattoos in both arms)

  • Incapacitated persons

  • Pregnant or breast-feeding

The following contra-indications / exclusion criteria are respected per arm:

  • Arteriovenous fistula or vascular graft

  • Paretic or paralyzed arm (e.g. after stroke or trauma)

  • Infected skin in cubital fossa (for example: erysipelas or cellulitis)

  • Mastectomy side, axillary lymph node excised

  • Healed skin burns in cubital fossa

  • Edema in cubital fossa

  • Extensive scarring in cubital fossa

  • Hematoma in cubital fossa

  • Tattoos in cubital fossa

In case the test subject has a suitable contralateral arm, the subject can be included in this study. In Study Phase B2, a manual venipuncture and automated venipuncture are performed in both arms. Patients who have a contra-indication in one arm are excluded from the Phase B2 study.

Study Design

Total Participants: 13618
Treatment Group(s): 1
Primary Treatment: Venipuncture Device (VD)
Phase:
Study Start date:
July 21, 2023
Estimated Completion Date:
July 31, 2025

Connect with a study center

  • Amsterdam UMC

    Amsterdam, Noord-Holland 1105 AZ
    Netherlands

    Active - Recruiting

  • OLVG Lab

    Amsterdam, Noord-Holland 1091 AC
    Netherlands

    Active - Recruiting

  • St. Antonius Hospital

    Nieuwegein, Utrecht 3435CM
    Netherlands

    Active - Recruiting

  • Result Laboratorium, location Albert Schweitzer Hospital

    Dordrecht, Zuid-Holland 3318 AT
    Netherlands

    Active - Recruiting

  • Vitestro

    Utrecht, 3526KS
    Netherlands

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.